Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Katarzyna Bachanek-Bankowska is active.

Publication


Featured researches published by Katarzyna Bachanek-Bankowska.


PLOS ONE | 2011

Complete Genome Characterisation of a Novel 26th Bluetongue Virus Serotype from Kuwait

Sushila Maan; Narender S. Maan; Kyriaki Nomikou; Eva Veronesi; Katarzyna Bachanek-Bankowska; Manjunatha N. Belaganahalli; Houssam Attoui; Peter P. C. Mertens

Bluetongue virus is the “type” species of the genus Orbivirus, family Reoviridae. Twenty four distinct bluetongue virus (BTV) serotypes have been recognized for decades, any of which is thought to be capable of causing “bluetongue” (BT), an insect-borne disease of ruminants. However, two further BTV serotypes, BTV-25 (Toggenburg orbivirus, from Switzerland) and BTV-26 (from Kuwait) have recently been identified in goats and sheep, respectively. The BTV genome is composed of ten segments of linear dsRNA, encoding 7 virus-structural proteins (VP1 to VP7) and four distinct non-structural (NS) proteins (NS1 to NS4). We report the entire BTV-26 genome sequence (isolate KUW2010/02) and comparisons to other orbiviruses. Highest identity levels were consistently detected with other BTV strains, identifying KUW2010/02 as BTV. The outer-core protein and major BTV serogroup-specific antigen “VP7” showed 98% aa sequence identity with BTV-25, indicating a common ancestry. However, higher level of variation in the nucleotide sequence of Seg-7 (81.2% identity) suggests strong conservation pressures on the protein of these two strains, and that they diverged a long time ago. Comparisons of Seg-2, encoding major outer-capsid component and cell-attachment protein “VP2” identified KUW2010/02 as 26th BTV, within a 12th Seg-2 nucleotype [nucleotype L]. Comparisons of Seg-6, encoding the smaller outer capsid protein VP5, also showed levels of nt/aa variation consistent with identification of KUW2010/02 as BTV-26 (within a 9th Seg-6 nucleotype - nucleotype I). Sequence data for Seg-2 of KUW2010/02 were used to design four sets of oligonucleotide primers for use in BTV-26, type-specific RT-PCR assays. Analyses of other more conserved genome segments placed KUW2010/02 and BTV-25/SWI2008/01 closer to each other than to other “eastern” or “western” BTV strains, but as representatives of two novel and distinct geographic groups (topotypes). Our analyses indicate that all of the BTV genome segments have evolved under strong purifying selection.


PLOS ONE | 2011

A Modified Vaccinia Ankara Virus (MVA) Vaccine Expressing African Horse Sickness Virus (AHSV) VP2 Protects Against AHSV Challenge in an IFNAR −/− Mouse Model

Javier Castillo-Olivares; Eva Calvo-Pinilla; Isabel Casanova; Katarzyna Bachanek-Bankowska; Rachael Chiam; Sushila Maan; José María Nieto; Javier Ortego; Peter P. C. Mertens

African horse sickness (AHS) is a lethal viral disease of equids, which is transmitted by Culicoides midges that become infected after biting a viraemic host. The use of live attenuated vaccines has been vital for the control of this disease in endemic regions. However, there are safety concerns over their use in non-endemic countries. Research efforts over the last two decades have therefore focused on developing alternative vaccines based on recombinant baculovirus or live viral vectors expressing structural components of the AHS virion. However, ethical and financial considerations, relating to the use of infected horses in high biosecurity installations, have made progress very slow. We have therefore assessed the potential of an experimental mouse-model for AHSV infection for vaccine and immunology research. We initially characterised AHSV infection in this model, then tested the protective efficacy of a recombinant vaccine based on modified vaccinia Ankara expressing AHS-4 VP2 (MVA-VP2).


Emerging Infectious Diseases | 2009

Transplacental transmission of bluetongue virus 8 in cattle, UK.

Karin E. Darpel; Carrie Batten; Eva Veronesi; Susanna Williamson; Peter Anderson; Mike Dennison; Stuart Clifford; Ciaran Smith; Lucy Philips; Cornelia Bidewell; Katarzyna Bachanek-Bankowska; Anna Sanders; Abid Bin-Tarif; Anthony J. Wilson; Simon Gubbins; Peter P. C. Mertens; C.A.L. Oura; Philip S. Mellor

To determine whether transplacental transmission could explain overwintering of bluetongue virus in the United Kingdom, we studied calves born to dams naturally infected during pregnancy in 2007–08. Approximately 33% were infected transplacentally; some had compromised health. In all infected calves, viral load decreased after birth; no evidence of persistent infection was found.


BMC Genomics | 2014

A universal protocol to generate consensus level genome sequences for foot-and-mouth disease virus and other positive-sense polyadenylated RNA viruses using the Illumina MiSeq

Grace Logan; Graham L. Freimanis; David J. King; Begoña Valdazo-González; Katarzyna Bachanek-Bankowska; Nicholas D Sanderson; Nick J. Knowles; Donald P. King; Eleanor M. Cottam

BackgroundNext-Generation Sequencing (NGS) is revolutionizing molecular epidemiology by providing new approaches to undertake whole genome sequencing (WGS) in diagnostic settings for a variety of human and veterinary pathogens. Previous sequencing protocols have been subject to biases such as those encountered during PCR amplification and cell culture, or are restricted by the need for large quantities of starting material. We describe here a simple and robust methodology for the generation of whole genome sequences on the Illumina MiSeq. This protocol is specific for foot-and-mouth disease virus (FMDV) or other polyadenylated RNA viruses and circumvents both the use of PCR and the requirement for large amounts of initial template.ResultsThe protocol was successfully validated using five FMDV positive clinical samples from the 2001 epidemic in the United Kingdom, as well as a panel of representative viruses from all seven serotypes. In addition, this protocol was successfully used to recover 94% of an FMDV genome that had previously been identified as cell culture negative. Genome sequences from three other non-FMDV polyadenylated RNA viruses (EMCV, ERAV, VESV) were also obtained with minor protocol amendments. We calculated that a minimum coverage depth of 22 reads was required to produce an accurate consensus sequence for FMDV O. This was achieved in 5 FMDV/O/UKG isolates and the type O FMDV from the serotype panel with the exception of the 5′ genomic termini and area immediately flanking the poly(C) region.ConclusionsWe have developed a universal WGS method for FMDV and other polyadenylated RNA viruses. This method works successfully from a limited quantity of starting material and eliminates the requirement for genome-specific PCR amplification. This protocol has the potential to generate consensus-level sequences within a routine high-throughput diagnostic environment.


PLOS ONE | 2013

Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2.

Tamara Jabbar; Eva Calvo-Pinilla; Francisco Mateos; Simon Gubbins; Abdelghani Bin-Tarif; Katarzyna Bachanek-Bankowska; Oya Alpar; Javier Ortego; Haru-Hisa Takamatsu; Peter P. C. Mertens; Javier Castillo-Olivares

The protective efficacy of recombinant vaccines expressing serotype 8 bluetongue virus (BTV-8) capsid proteins was tested in a mouse model. The recombinant vaccines comprised plasmid DNA or Modified Vaccinia Ankara viruses encoding BTV VP2, VP5 or VP7 proteins. These constructs were administered alone or in combination using either a homologous prime boost vaccination regime (rMVA/rMVA) or a heterologous vaccination regime (DNA/rMVA). The DNA/rMVA or rMVA/rMVA prime-boost were administered at a three week interval and all of the animals that received VP2 generated neutralising antibodies. The vaccinated and non-vaccinated-control mice were subsequently challenged with a lethal dose of BTV-8. Mice vaccinated with VP7 alone were not protected. However, mice vaccinated with DNA/rMVA or rMVA/rMVA expressing VP2, VP5 and VP7 or VP2 alone were all protected.


Vaccine | 2014

Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge

Berta Alberca; Katarzyna Bachanek-Bankowska; Marta Cabana; Eva Calvo-Pinilla; Elisenda Viaplana; Lorraine Frost; Simon Gubbins; Alicia Urniza; Peter P. C. Mertens; Javier Castillo-Olivares

Highlights • A recombinant modified Vaccinia Ankara virus expressing VP2 of African horse sickness virus serotype 9 was generated.• Four horses were vaccinated on days 0 and 20. Three unvaccinated controls were used.• Vaccinated and control horses were challenged intravenously with 107.4TCID50 of AHSV-9 on day 34 of the study.• At challenge, vaccinates had virus neutralising antibodies but were negative for antibodies to AHSV-VP7.• All vaccinates were completely protected against clinical signs of African horse sickness.


Antiviral Research | 2014

Characterization of sheep pox virus vaccine for cattle against lumpy skin disease virus.

Eeva Tuppurainen; Caroline R. Pearson; Katarzyna Bachanek-Bankowska; Nick J. Knowles; Shadi Amareen; Lorraine Frost; Mark Henstock; Charles Euloge Lamien; Adama Diallo; Peter P. C. Mertens

Highlights • KSGP O-240 strain was identified as lumpy skin disease virus.• Commercially available KSGP O-240 vaccines should be re-characterized.• The safety of these vaccines in cattle against LSDV should be re-evaluated.• Two GTPV candidates were identified for use as a broad-spectrum capripox vaccine.


BMC Veterinary Research | 2013

Detection of capripoxvirus DNA using a novel loop-mediated isothermal amplification assay

Lee Murray; L. Edwards; Eeva Tuppurainen; Katarzyna Bachanek-Bankowska; C.A.L. Oura; Valerie Mioulet; Donald P. King

BackgroundSheep poxvirus (SPPV), Goat poxvirus (GTPV) and Lumpy skin disease virus (LSDV) are the most serious poxviruses of ruminants. They are double stranded DNA viruses of the genus Capripoxvirus, (subfamily Chordopoxvirinae) within the family Poxviridae. The aim of this study was to develop a Loop-mediated isothermal AMPlification (LAMP) assay for the detection of Capripoxvirus (CaPV) DNA.ResultsA single LAMP assay targeting a conserved region of the CaPV P32 gene was selected from 3 pilot LAMP assays and optimised by adding loop primers to accelerate the reaction time. This LAMP assay successfully detected DNA prepared from representative CaPV isolates (SPPV, GTPV and LSDV), and did not cross-react with DNA extracted from other mammalian poxviruses. The analytical sensitivity of the LAMP assay was determined to be at least 163 DNA copies/μl which is equivalent to the performance reported for diagnostic real-time PCR currently used for the detection of CaPV. LAMP reactions were monitored with an intercalating dye using a real-time PCR machine, or by agarose-gel electrophoresis. Furthermore, dual labelled LAMP products (generated using internal LAMP primers that were conjugated with either biotin or fluorescein) could be readily visualised using a lateral-flow device.ConclusionsThis study provides a simple and rapid approach to detect CaPV DNA that may have utility for use in the field, or in non-specialised laboratories where expensive equipment is not available.


PLOS ONE | 2014

Real time RT-PCR assays for detection and typing of African horse sickness virus.

Katarzyna Bachanek-Bankowska; Sushila Maan; Javier Castillo-Olivares; Nicola Mary Manning; Narender S. Maan; Abraham C. Potgieter; Antonello Di Nardo; Geoff Sutton; Carrie Batten; Peter P. C. Mertens

Although African horse sickness (AHS) can cause up to 95% mortality in horses, naïve animals can be protected by vaccination against the homologous AHSV serotype. Genome segment 2 (Seg-2) encodes outer capsid protein VP2, the most variable of the AHSV proteins. VP2 is also a primary target for AHSV specific neutralising antibodies, and consequently determines the identity of the nine AHSV serotypes. In contrast VP1 (the viral polymerase) and VP3 (the sub-core shell protein), encoded by Seg-1 and Seg-3 respectively, are highly conserved, representing virus species/orbivirus-serogroup-specific antigens. We report development and evaluation of real-time RT-PCR assays targeting AHSV Seg-1 or Seg-3, that can detect any AHSV type (virus species/serogroup-specific assays), as well as type-specific assays targeting Seg-2 of the nine AHSV serotypes. These assays were evaluated using isolates of different AHSV serotypes and other closely related orbiviruses, from the ‘Orbivirus Reference Collection’ (ORC) at The Pirbright Institute. The assays were shown to be AHSV virus-species-specific, or type-specific (as designed) and can be used for rapid, sensitive and reliable detection and identification (typing) of AHSV RNA in infected blood, tissue samples, homogenised Culicoides, or tissue culture supernatant. None of the assays amplified cDNAs from closely related heterologous orbiviruses, or from uninfected host animals or cell cultures.


PLOS ONE | 2011

Serotype Specific Primers and Gel-Based RT-PCR Assays for ‘Typing’ African Horse Sickness Virus: Identification of Strains from Africa

Narender S. Maan; Sushila Maan; Kyriaki Nomikou; Manjunatha N. Belaganahalli; Katarzyna Bachanek-Bankowska; Peter P. C. Mertens

African horse sickness is a devastating, transboundary animal disease, that is ‘listed’ by the Office International des Epizooties (OIE). Although attenuated, inactivated and subunit vaccines have been developed for African horse sickness virus (AHSV), these are serotype-specific and their effective deployment therefore relies on rapid and reliable identification of virus type. AHSV serotype is controlled by the specificity of interactions between neutralising antibodies, and components of the outer-capsid, particularly protein VP2 (encoded by AHSV genome segment 2 (Seg-2)). We report the development and evaluation of novel gel based reverse transcription-PCR (RT–PCR) assays targeting AHSV Seg-2, which can be used to very significantly increase the speed and reliability of detection and identification (compared to virus neutralisation tests) of the nine serotypes of AHSV. Primer sets were designed targeting regions of Seg-2 that are conserved between strains within each of the AHSV serotype (types 1 to 9). These assays were evaluated using multiple AHSV strains from the orbivirus reference collection at IAH (www.reoviridae.org/dsRNA_virus_proteins/ReoID/AHSV-isolates.htm). In each case the Seg-2 primers showed a high level of specificity and failed to cross-amplify the most closely related heterologous AHSV types, or other related orbiviruses (such as bluetongue virus (BTV), or equine encephalosis virus (EEV)). The assays are rapid and sensitive, and can be used to detect and type viral RNA in blood, tissue samples, or cultivated viral suspensions within 24 h. They were used to identify AHSV strains from recent outbreaks in sub-Saharan African countries. These methods also generate cDNAs suitable for sequencing and phylogenetic analyses of Seg-2, identifying distinct virus lineages within each virus-type and helping to identify strain movements/origins. The RT-PCR methods described here provide a robust and versatile tool for rapid and specific detection and identification of AHSV serotypes 1 to 9.

Collaboration


Dive into the Katarzyna Bachanek-Bankowska's collaboration.

Top Co-Authors

Avatar

Donald P. King

Institute for Animal Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Nick J. Knowles

Institute for Animal Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jemma Wadsworth

Institute for Animal Health

View shared research outputs
Top Co-Authors

Avatar

Simon Gubbins

Institute for Animal Health

View shared research outputs
Top Co-Authors

Avatar

Sushila Maan

Lala Lajpat Rai University of Veterinary and Animal Sciences

View shared research outputs
Top Co-Authors

Avatar

Antonello Di Nardo

Institute for Animal Health

View shared research outputs
Top Co-Authors

Avatar

Carrie Batten

Institute for Animal Health

View shared research outputs
Top Co-Authors

Avatar

Eva Calvo-Pinilla

Institute for Animal Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge